Publicaciones en colaboración con investigadores/as de Stanford University School of Medicine (13)

2024

  1. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

    Nature Genetics, Vol. 56, Núm. 10, pp. 2121-2131

2023

  1. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2020

  1. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies

    Blood, Vol. 131, Núm. 1, pp. 49-57

2017

  1. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

    Nature Communications, Vol. 8

  2. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 389, Núm. 10064, pp. 67-76

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

  2. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

    Annals of Oncology, Vol. 27, Núm. 7, pp. 1190-1198

2015

  1. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137

2011

  1. Tumor-stromal interactions of the bone microenvironment: In vitro findings and potential in vivo relevance in metastatic lung cancer models

    Clinical and Experimental Metastasis, Vol. 28, Núm. 8, pp. 779-791